Yimeng OncoBio Pharmaceutical (1541) said HKEX has questioned whether a partial exemption applies to a loan transaction involving its chairman, according to Ming Pao.
The company, which listed in September 2023, announced in February that it would provide a one-year loan of about RMB13.4247 million to chairman Tian Wenzhi for tax compliance purposes, with interest linked to the National Interbank Funding Center’s one-year quoted rate.
It said HKEX sent a letter on June 24 stating the partial exemption clause does not apply. HKEX said the transaction requires an independent financial adviser’s opinion and approval by independent shareholders.
STOCKS | Yimeng OncoBio Says HKEX Questions Loan Exemption; Independent Approval Needed
2026-07-02 15:37:20
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
